semaglutide dr reddy's gets regulatory nod to sell generic Ozempic in India, targets 12 million pens in first year India's Dr Reddy's plans to

Figure 1: FDA Approved Incretin Mimetic (GLP-1 and dual agonist) Diabetes and Obesity Products (as of December 2023) The Future of Incretin Mimetics in Diabetes and Obesity Looking Forward GLP-1 Clinical Development Pipeline Looking Forward GLP-1 Clinical Development Pipeline While Novo Nordisk and Eli Lilly dominate todays market, the success of incretin mimetics has attracted greater interest and investment, with a slew of potential new players aiming to enter and carve out their own space

This means that, in addition to appetite control, semaglutide medications help you burn calories more efficiently, even when you are not active

For many patients treated with both conditions, combination therapy delivers the best results

It can also be caused by physical obstructions such as food and waste material